GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Cyclically Adjusted Revenue per Share

Cardiff Oncology (Cardiff Oncology) Cyclically Adjusted Revenue per Share : $0.49 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cardiff Oncology's adjusted revenue per share for the three months ended in Mar. 2024 was $0.005. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.49 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Cardiff Oncology's average Cyclically Adjusted Revenue Growth Rate was -19.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cardiff Oncology was -20.60% per year. The lowest was -20.60% per year. And the median was -20.60% per year.

As of today (2024-05-14), Cardiff Oncology's current stock price is $3.58. Cardiff Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.49. Cardiff Oncology's Cyclically Adjusted PS Ratio of today is 7.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cardiff Oncology was 19.75. The lowest was 1.41. And the median was 3.12.


Cardiff Oncology Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Cardiff Oncology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Cyclically Adjusted Revenue per Share Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.08 0.91 0.67 0.54

Cardiff Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.59 0.57 0.54 0.49

Competitive Comparison of Cardiff Oncology's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PS Ratio falls into.



Cardiff Oncology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cardiff Oncology's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.005/129.4194*129.4194
=0.005

Current CPI (Mar. 2024) = 129.4194.

Cardiff Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.210 100.560 0.270
201409 0.217 100.428 0.280
201412 0.210 99.070 0.274
201503 0.419 99.621 0.544
201506 0.173 100.684 0.222
201509 0.141 100.392 0.182
201512 0.189 99.792 0.245
201603 0.287 100.470 0.370
201606 0.248 101.688 0.316
201609 0.211 101.861 0.268
201612 0.159 101.863 0.202
201703 0.221 102.862 0.278
201706 0.237 103.349 0.297
201709 0.243 104.136 0.302
201712 0.331 104.011 0.412
201803 0.130 105.290 0.160
201806 0.091 106.317 0.111
201809 0.026 106.507 0.032
201812 0.020 105.998 0.024
201903 0.015 107.251 0.018
201906 0.007 108.070 0.008
201909 0.009 108.329 0.011
201912 0.011 108.420 0.013
202003 0.007 108.902 0.008
202006 0.003 108.767 0.004
202009 0.006 109.815 0.007
202012 0.003 109.897 0.004
202103 0.002 111.754 0.002
202106 0.002 114.631 0.002
202109 0.002 115.734 0.002
202112 0.003 117.630 0.003
202203 0.002 121.301 0.002
202206 0.002 125.017 0.002
202209 0.002 125.227 0.002
202212 0.003 125.222 0.003
202303 0.002 127.348 0.002
202306 0.002 128.729 0.002
202309 0.003 129.860 0.003
202312 0.003 129.419 0.003
202403 0.005 129.419 0.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Cardiff Oncology  (NAS:CRDF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cardiff Oncology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.58/0.49
=7.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cardiff Oncology was 19.75. The lowest was 1.41. And the median was 3.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cardiff Oncology Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (Cardiff Oncology) Business Description

Industry
Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
Executives
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116